Skip to main content
PMC home page
Brain Pathology logoLink to Brain Pathology
. 2006 Apr 5;13(1):95–103. doi: 10.1111/j.1750-3639.2003.tb00010.x

HIV‐1 Persistence, Viral Reservoir, and the Central Nervous System in the HAART Era

Olivier Lambotte 1, Kumaran Deiva 1, Marc Tardieu 1,✉
PMCID: PMC8095761  PMID: 12580549

Abstract

HAART therapy has led to a significant reduction of general and neurological morbidity, and mortality among HIV‐1 infected patients. It can also decrease HIV‐1 RNA titres in plasma and CSF towards undetectable level. However, the initial hope of achieving total eradication of the virus from the body has vanished. Even in patients who do not develop viral resistance or treatment intolerance, two kinds of viral persistence have been demonstrated both in lymphoid and central nervous system. The first one is a smoldering infection that persists, despite prolonged and apparently efficient HAART, in monocytes, tissue macrophages and most probably microglia. The second one is an integration of proviral DNA in the genome of subpopulations of CD4 lymphocytes of patients receiving efficient HAART. A similar viral integration in astrocytes and less likely in resting microglia is suggested by several studies, although it has yet to be demonstrated conclusively

Full Text

The Full Text of this article is available as a PDF (48.1 KB).

References

  • 1. Al‐Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M and Landay A (2000) Maximum suppression of HIV replication leads to the restoration of HIV‐ specific responses in early HIV disease. AIDS 14:761–770. [DOI] [PubMed] [Google Scholar]
  • 2. Angel JB, Parato KG, Kumar A, Kravcik S, Badley AD, Fex C, Ashby D, Sun E and Cameron DW (2001) Progressive human immunodeficiency virus‐specific immune recovery with prolonged viral suppression. J Infect Dis 183:546–554. [DOI] [PubMed] [Google Scholar]
  • 3. Autran B, Carcelain G, Li TS, Blanc C, Mathez D, Tubiana R, Katlama C, Debre P and Leibowitch J (1997) Positive effects of combined antiretroviral therapy on CD4+ T‐cell homeostasis and function in advanced HIV disease. Science 277:112–116. [DOI] [PubMed] [Google Scholar]
  • 4. Blankson JN, Persaud D and Siliciano RF (2002) The challenge of viral reservoirs in HIV‐1 infection. Annu Rev Med 53:557–593. [DOI] [PubMed] [Google Scholar]
  • 5. Boutet A, Salim H, Leclerc P and Tardieu M (2001) Cellular expression of functional chemokine receptor CCR5 and CXCR4 in human embryonic neurons. Neurosci Lett 311:105–108. [DOI] [PubMed] [Google Scholar]
  • 6. Brack‐Werner R (1999) Astrocytes: HIV cellular reservoirs and important participants in neuropathogenesis. AIDS 13:1–22. [DOI] [PubMed] [Google Scholar]
  • 7. Brooks DG, Kitchen SG, Kitchen CM, Scripture‐Adams DD and Zack JA (2001) Generation of HIV latency during thymopoiesis. Nat Med 7:459–464. [DOI] [PubMed] [Google Scholar]
  • 8. Butler SL, Johnson EP and Bushman FD (2002) Human immunodeficiency virus cDNA metabolism: notable stability of two‐long terminal repeat circles. J Virol 76:3739–3747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Chun TW, Engel D, Berrey MM, Shea T, Corey L and Fauci AS (1998) Early establishment of a pool of latently infected, resting CD4(+) T‐cells during primary HIV‐1 infection. Proc Natl Acad Sci U S A 95:8869–8873. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, Lloyd AL, Nowak MA and Fauci AS (1997) Presence of an inducible HIV‐1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94:13193–13197. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Cinque P, Presi S, Bestetti A, Pierotti C, Racca S, Boeri E, Morelli P, Carrera P, Ferrari M and Lazzarin A (2001) Effect of genotypic resistance on the virological response to highly active antiretroviral therapy in cerebrospinal fluid. AIDS Res Hum Retroviruses 17:377–383. [DOI] [PubMed] [Google Scholar]
  • 12. Cinque P, Vago L, Ceresa D, Mainini F, Terreni MR, Vagani A, Torri W, Bossolasco S and Lazzarin A (1998) Cerebrospinal fluid HIV‐1 RNA levels: correlation with HIV encephalitis. AIDS 12:389–394. [DOI] [PubMed] [Google Scholar]
  • 13. Cunningham PH, Smith DG, Satchell C, Cooper DA and Brew B (2000) Evidence for independent development of resistance to HIV‐1 reverse transcriptase inhibitors in the cerebrospinal fluid. AIDS 14:1949–1954. [DOI] [PubMed] [Google Scholar]
  • 14. D'Arminio Monforte A, Duca PG, Vago L, Grassi MP and Moroni M (2000) Decreasing incidence of CNS AIDS‐defining events associated with antiretroviral therapy. Neurology 54:1856–1859. [DOI] [PubMed] [Google Scholar]
  • 15. Davey RT, Jr. , Bhat N, Yoder C, Chun TW, Metcalf JA, Dewar R, Natarajan V, Lempicki RA, Adelsberger JW, Miller KD, Kovacs JA, Polis MA, Walker RE, Falloon J, Masur H, Gee D, Baseler M, Dimitrov DS, Fauci AS and Lane HC (1999) HIV‐1 and T‐cell dynamics after interruption of highly active antiretroviral therapy (HAART) in patients with a history of sustained viral suppression. Proc Natl Acad Sci U S A 96:15109–15114. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16. Demoustier A, Gubler B, Lambotte O, de Goër MG, Wallon C, Goujard C, Delfraissy J and Taoufik Y (2002) In patients on prolonged HAART, a significant pool of HIV infected CD4 T‐cells are HIV‐specific. AIDS in press. [DOI] [PubMed] [Google Scholar]
  • 17. Di Stefano M, Monno L, Fiore JR, Buccoliero G, Appice A, Perulli LM, Pastore G and Angarano G (1998) Neurological disorders during HIV‐1 infection correlate with viral load in cerebrospinal fluid but not with virus phenotype. AIDS 12:737–743. [DOI] [PubMed] [Google Scholar]
  • 18. Dornadula G, Zhang H, VanUitert B, Stern J, Livornese L, Jr. , Ingerman MJ, Witek J, Kedanis RJ, Natkin J, DeSimone J and Pomerantz RJ (1999) Residual HIV‐1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy. JAMA 282:1627–1632. [DOI] [PubMed] [Google Scholar]
  • 19. Douek DC, Brenchley JM, Betts MR, Ambrozak DR, Hill BJ, Okamoto Y, Casazza JP, Kuruppu J, Kunstman K, Wolinsky S, Grossman Z, Dybul M, Oxenius A, Price DA, Connors M and Koup RA (2002) HIV preferentially infects HIV‐specific CD4+ T‐cells. Nature 417:95–98. [DOI] [PubMed] [Google Scholar]
  • 20. Ellis RJ, Gamst AC, Capparelli E, Spector SA, Hsia K, Wolfson T, Abramson I, Grant I and McCutchan JA (2000) Cerebrospinal fluid HIV RNA originates from both local CNS and systemic sources. Neurology 54:927–936. [DOI] [PubMed] [Google Scholar]
  • 21. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, Quinn TC, Chadwick K, Margolick J, Brookmeyer R, Gallant J, Markowitz M, Ho DD, Richman DD and Siliciano RF (1997) Identification of a reservoir for HIV‐1 in patients on highly active antiretroviral therapy. Science 278:1295–1300. [DOI] [PubMed] [Google Scholar]
  • 22. Furtado MR, Callaway DS, Phair JP, Kunstman KJ, Stanton JL, Macken CA, Perelson AS and Wolinsky SM (1999) Persistence of HIV‐1 transcription in peripheral‐blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 340:1614–1622. [DOI] [PubMed] [Google Scholar]
  • 23. Gea‐Banacloche JC and Clifford Lane H (1999) Immune reconstitution in HIV infection. AIDS 13:S25–38. [PubMed] [Google Scholar]
  • 24. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG and van Kooyk Y (2000) DC‐SIGN, a dendritic cell‐specific HIV‐1‐binding protein that enhances trans‐infection of T‐cells. Cell 100:587–597. [DOI] [PubMed] [Google Scholar]
  • 25. Gorry PR, Howard JL, Churchill MJ, Anderson JL, Cunningham A, Adrian D, McPhee DA and Purcell DF (1999) Diminished production of human immunodeficiency virus type 1 in astrocytes results from inefficient translation of gag, env, and nef mRNAs despite efficient expression of Tat and Rev. J Virol 73:352–361. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Greene WC and Peterlin BM (2002) Charting HIV's remarkable voyage through the cell: Basic science as a passport to future therapy. Nat Med 8:673–680. [DOI] [PubMed] [Google Scholar]
  • 27. Groothuis DR and Levy RM (1997) The entry of antiviral and antiretroviral drugs into the central nervous system. J Neurovirol 3:387–400. [DOI] [PubMed] [Google Scholar]
  • 28. Harouse JM, Laughlin MA, Pletcher C, Friedman HM and Gonzalez‐Scarano F (1991) Entry of human immunodeficiency virus‐1 into glial cells proceeds via an alternate, efficient pathway. J Leukoc Biol 49:605–609. [DOI] [PubMed] [Google Scholar]
  • 29. Harrigan PR, Whaley M and Montaner JS (1999) Rate of HIV‐1 RNA rebound upon stopping antiretroviral therapy. AIDS 13:F59–62. [DOI] [PubMed] [Google Scholar]
  • 30. Hess C, Klimkait T, Schlapbach L, Del Zenero V, Sadallah S, Horakova E, Balestra G, Werder V, Schaefer C, Battegay M and Schifferli JA (2002) Association of a pool of HIV‐1 with erythrocytes in vivo: a cohort study. Lancet 359:2230–2234. [DOI] [PubMed] [Google Scholar]
  • 31. Lambotte O, Demoustier A, de Goër M, Wallon C, Gasnaut J, Goujard C, Delfraissy J and Taoufik Y (2002) Persistence of replication‐competent HIV in both memory and naive CD4+ T‐cell subsets in patients on prolonged and effective HAART. AIDS in press. [DOI] [PubMed] [Google Scholar]
  • 32. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C and Delfraissy JF (2000) Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J AIDS 23:114–119. [DOI] [PubMed] [Google Scholar]
  • 33. Langford TD, Letendre SL, Marcotte TD, Ellis RJ, McCutchan JA, Grant I, Mallory ME, Hansen LA, Archibald S, Jernigan T and Masliah E (2002) Severe, demyelinating leukoencephalopathy in AIDS patients on antiretroviral therapy. AIDS 16:1019–1029. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I and Dey S (1998) HIV‐1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594–3601. [DOI] [PubMed] [Google Scholar]
  • 35. Masliah E, DeTeresa RM, Mallory ME and Hansen LA (2000) Changes in pathological findings at autopsy in AIDS cases for the last 15 years. AIDS 14:69–74. [DOI] [PubMed] [Google Scholar]
  • 36. Michie CA, McLean A, Alcock C and Beverley PC (1992) Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature 360:264–265. [DOI] [PubMed] [Google Scholar]
  • 37. Neumann M, Felber BK, Kleinschmidt A, Froese B, Erfle V, Pavlakis GN and Brack‐Werner R (1995) Restriction of human immunodeficiency virus type 1 production in a human astrocytoma cell line is associated with a cellular block in Rev function. J Virol 69:2159–2167. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 38. Ostrowski MA, Chun TW, Justement SJ, Motola I, Spinelli MA, Adelsberger J, Ehler LA, Mizell SB, Hallahan CW and Fauci AS (1999) Both memory and CD45RA+/CD62L+ naive CD4(+) T‐cells are infected in human immunodeficiency virus type 1‐infected individuals. J Virol 73:6430–6435. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Pakker NG, Notermans DW, de Boer RJ, Roos MT, de Wolf F, Hill A, Leonard JM, Danner SA, Miedema F and Schellekens PT (1998) Biphasic kinetics of peripheral blood T‐cells after triple combination therapy in HIV‐1 infection: a composite of redistribution and proliferation. Nat Med 4:208–214. [DOI] [PubMed] [Google Scholar]
  • 40. Perelson AS, Essunger P, Cao Y, Vesanen M, Hurley A, Saksela K, Markowitz M and Ho DD (1997) Decay characteristics of HIV‐1‐infected compartments during combination therapy. Nature 387:188–191. [DOI] [PubMed] [Google Scholar]
  • 41. Perno CF, Newcomb FM, Davis DA, Aquaro S, Humphrey RW, Calio R and Yarchoan R (1998) Relative potency of protease inhibitors in monocytes/macrophages acutely and chronically infected with human immunodeficiency virus. J Infect Dis 178:413–422. [DOI] [PubMed] [Google Scholar]
  • 42. Pierson TC, Kieffer TL, Ruff CT, Buck C, Gange SJ and Siliciano RF (2002) Intrinsic stability of episomal circles formed during human immunodeficiency virus type 1 replication. J Virol 76:4138–4144. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43. Pierson TC, Zhou Y, Kieffer TL, Ruff CT, Buck C and Siliciano RF (2002) Molecular characterization of preintegration latency in human immunodeficiency virus type 1 infection. J Virol 76:8518–8531. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Pitcher CJ, Quittner C, Peterson DM, Connors M, Koup RA, Maino VC and Picker LJ (1999) HIV‐1‐specific CD4+ T‐cells are detectable in most individuals with active HIV‐1 infection, but decline with prolonged viral suppression. Nat Med 5:518–525. [DOI] [PubMed] [Google Scholar]
  • 45. Pratt RD, Nichols S, McKinney N, Kwok S, Dankner WM and Spector SA (1996) Virologic markers of human immunodeficiency virus type 1 in cerebrospinal fluid of infected children. J Infect Dis 174:288–293. [DOI] [PubMed] [Google Scholar]
  • 46. Price RW, Paxinos EE, Grant RM, Drews B, Nilsson A, Hoh R, Hellmann NS, Petropoulos CJ and Deeks SG (2001) Cerebrospinal fluid response to structured treatment interruption after virological failure. AIDS 15:1251–1259. [DOI] [PubMed] [Google Scholar]
  • 47. Price RW, Yiannoutsos CT, Clifford DB, Zaborski L, Tselis A, Sidtis JJ, Cohen B, Hall CD, Erice A and Henry K (1999) Neurological outcomes in late HIV infection: adverse impact of neurological impairment on survival and protective effect of antiviral therapy. AIDS Clinical Trial Group and Neurological AIDS Research Consortium study team. AIDS 13:1677–1685. [DOI] [PubMed] [Google Scholar]
  • 48. Sacktor NC, Lyles RH, Skolasky RL, Anderson DE, McArthur JC, McFarlane G, Selnes OA, Becker JT, Cohen B, Wesch J and Miller EN (1999) Combination antiretroviral therapy improves psychomotor speed performance in HIV‐seropositive homosexual men. Multi‐center AIDS Cohort Study (MACS). Neurology 52:1640–1647. [DOI] [PubMed] [Google Scholar]
  • 49. Saito Y, Sharer LR, Epstein LG, Michaels J, Mintz M, Louder M, Golding K, Cvetkovich TA and Blumberg BM (1994) Overexpression of nef as a marker for restricted HIV‐1 infection of astrocytes in postmortem pediatric central nervous tissues. Neurology 44:474–481. [DOI] [PubMed] [Google Scholar]
  • 50. Schnitzer JE (2001) Caveolae: from basic trafficking mechanisms to targeting transcytosis for tissue‐specific drug and gene delivery in vivo. Adv Drug Deliv Rev 49:265–280. [DOI] [PubMed] [Google Scholar]
  • 51. Schrager LK and D'Souza MP (1998) Cellular and anatomical reservoirs of HIV‐1 in patients receiving potent antiretroviral combination therapy. JAMA 280:67–71. [DOI] [PubMed] [Google Scholar]
  • 52. Sharkey ME, Teo I, Greenough T, Sharova N, Luzuriaga K, Sullivan JL, Bucy RP, Kostrikis LG, Haase A, Veryard C, Davaro RE, Cheeseman SH, Daly JS, Bova C, Ellison RT, 3rd , Mady B, Lai KK, Moyle G, Nelson M, Gazzard B, Shaunak S and Stevenson M (2000) Persistence of episomal HIV‐1 infection intermediates in patients on highly active antiretroviral therapy. Nat Med 6:76–81. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53. Smith BA, Gartner S, Liu Y, Perelson AS, Stilianakis NI, Keele BF, Kerkering TM, Ferreira‐Gonzalez A, Szakal AK, Tew JG and Burton GF (2001) Persistence of infectious HIV on follicular dendritic cells. J Immunol 166:690–696. [DOI] [PubMed] [Google Scholar]
  • 54. Staprans S, Marlowe N, Glidden D, Novakovic‐Agopian T, Grant RM, Heyes M, Aweeka F, Deeks S and Price RW (1999) Time course of cerebrospinal fluid responses to antiretroviral therapy: evidence for variable compartmentalization of infection. AIDS 13:1051–1061. [DOI] [PubMed] [Google Scholar]
  • 55. Tardieu M and Boutet A (2002) HIV‐1 and the central nervous system. Curr Top Microbiol Immunol 265:183–195. [DOI] [PubMed] [Google Scholar]
  • 56. Tornatore C, Chandra R, Berger JR and Major EO (1994) HIV‐1 infection of subcortical astrocytes in the pediatric central nervous system. Neurology 44:481–487. [DOI] [PubMed] [Google Scholar]
  • 57. Tozzi V, Balestra P, Galgani S, Narciso P, Ferri F, Sebastiani G, D'Amato C, Affricano C, Pigorini F, Pau FM, de Felici A and Benedetto A (1999) Positive and sustained effects of highly active antiretroviral therapy on HIV‐1‐associated neurocognitive impairment. AIDS 13:1889–1897. [DOI] [PubMed] [Google Scholar]
  • 58. Valentin A, Rosati M, Patenaude DJ, Hatzakis A, Kostrikis LG, Lazanas M, Wyvill KM, Yarchoan R and Pavlakis GN (2002) Persistent HIV‐1 infection of natural killer cells in patients receiving highly active antiretroviral therapy. Proc Natl Acad Sci U S A 99:7015–7020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59. van der Sandt IC, Vos CM, Nabulsi L, Blom‐Roosemalen MC, Voorwinden HH, de Boer AG and Breimer DD (2001) Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood—brain barrier. AIDS 15:483–491. [DOI] [PubMed] [Google Scholar]
  • 60. Venturi G, Catucci M, Romano L, Corsi P, Leoncini F, Valensin PE and Zazzi M (2000) Antiretroviral resistance mutations in human immunodeficiency virus type 1 reverse transcriptase and protease from paired cerebrospinal fluid and plasma samples. J Infect Dis 181:740–745. [DOI] [PubMed] [Google Scholar]
  • 61. Wang J, Crawford K, Yuan M, Wang H, Gorry PR and Gabuzda D (2002) Regulation of CC chemokine receptor 5 and CD4 expression and human immunodeficiency virus type 1 replication in human macrophages and microglia by T helper type 2 cytokines. J Infect Dis 185:885–897. [DOI] [PubMed] [Google Scholar]
  • 62. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA and Richman DD (1997) Recovery of replication‐competent HIV despite prolonged suppression of plasma viremia. Science 278:1291–1295. [DOI] [PubMed] [Google Scholar]
  • 63. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ and Richman DD (1997) In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 71:2059–2071. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 64. Zhang L, Ramratnam B, Tenner‐Racz K, He Y, Vesanen M, Lewin S, Talal A, Racz P, Perelson AS, Korber BT, Markowitz M and Ho DD (1999) Quantifying residual HIV‐1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 340:1605–1613. [DOI] [PubMed] [Google Scholar]

Articles from Brain Pathology are provided here courtesy of Wiley

RESOURCES